M3, a natural lignan xyloside, exhibits potent anticancer activity in HCT116 cells

WEIDONG SHEN¹, YU ZHAO², HAIJIAO CHEN³, TING ZHANG³, SHENBAO WU⁴ and PENGFEI LIU¹

¹Department of Gastroenterology, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, Jiangsu 214400; ²School of Pharmacy, Nantong University, Nantong, Jiangsu 226019; ³Department of Center Laboratory, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, Jiangsu 214400; ⁴Department of Gastroenterology, The Affiliated Yiwu Hospital of Wenzhou Medical College, Yiwu, Zhejiang 322000, P.R. China

Received January 18, 2018; Accepted October 12, 2018

DOI: 10.3892/ol.2018.9823

Abstract. 4-O-(2',3',4'-tri-O-methyl-β-D-xylopyranosyl) diphyllin (M3) is a cytotoxic compound that was first isolated from the aerial parts of Phyllanthus taxodifolius. The current study demonstrated that M3, a lignan xyloside, exhibits anticancer effects in a number of cancer cell lines by MTT test, including HCT116 cells. An association was identified between M3 treatment and the reduced proliferation of cancer cells; the half maximal inhibitory concentration (IC₅₀) value of M3 ranged from 0.08 to 1.12 µM. Furthermore, M3 was revealed to exhibit a stronger antiproliferative effect by Annexin-V-FLUOS test compared with VP-16, another natural lignan used in cancer treatment. Notably, the IC₅₀ value of M3 with MTT test in HCT116 cells was 0.08 µM. In addition, it was revealed that M3 could induce apoptosis in HCT116 cells in a caspase-3-dependent manner at a lower concentration compared with VP-16. Further analysis identified that the antiproliferation effect of M3 was associated with the promotion of microtubule polymerization by CytoDYNAMIX Screen 03 Tubulin Polymerization assay. In summary, the current study demonstrated that M3 could inhibit proliferation and induce apoptosis in HCT116 cells, which supports a potential therapeutic application of M3 in cancer treatment, particularly in colon cancer.

Introduction

Glycosylated natural products contain sugar attachments that are essential for their biological activities (1). The attached sugars can influence the shape or the physical properties of a molecule and significantly affect the biological activity (2,3). A number of studies have investigated the development of novel glycosylated compounds.

Lignans, particularly arylnaphthalene lignans, including podophyllotoxin, have widely been used in the design and synthesis of anticancer drugs, and the structure-activity associations of these molecules have been extensively studied (4-6). Diphyllin, an arylnaphthalene lignan lactone that is isolated from numerous traditional medicinal plants, has been identified to possess numerous anticancer and antiviral activities (5-7). Diphyllin exhibits tumoricidal effects similar to those of VP-16, with IC₅₀ values ranging from 10⁻⁶ to 10⁻⁴ M (8). VP-16, another type of natural lignan, has been used clinically in cancer treatment; however, side effects include toxic bone marrow arrest and neurotoxicity (6). Previous studies have identified that glycans serve a crucial role in determining the specificity and potency of arylnaphthalene lignans, including diphyllin, against tumor cells (7-9). In a previous study, we synthesized two cytotoxic diphyllin glycosides, cleistanthin-A and cleistanthoside-A tetraacetate, which are vacuolar H⁺-ATPase inhibitors (9) that exhibit a higher cytotoxic activity in HCT116 and HepG2 cells compared with diphyllin (3,4).

Certain diphyllin glycosides exhibit inhibitory effects on cancer cell proliferation and on DNA topoisomerase II (4,10,11). However, the inhibition of DNA topoisomerase II activity was not identified to be associated with the inhibition of proliferation, which promoted studies to investigate the mode of action of diphyllin glycosides (3,11). Previous studies have demonstrated that podophllotoxin compounds, including VP-16, can inhibit the formation of microtubules (12,13). Microtubule polymerization and depolymerization kinetics are required for cell mitosis (4). Instead of performing plant extraction, the current study synthesized the lignan xyloside 4-O-(2',3',4'-tri-O-methyl-β-D-xylopyranosyl) diphyllin (M3) in sufficient quantities for subsequent experiments. VP-16 is a lignan-containing glucose structure, while M3 is a naphthyl lignan with a xylose structure (3,12). We hypothesized that
M3, with the additional sugar attachments, exhibits stronger antitumor effects compared with VP-16, acting through the inhibition of the proliferation of tumor cells and promoting tumor cell apoptosis through the inhibition of microtubule formation.

Materials and methods

Drugs and reagents. The compound M3 (Fig. 1A) was synthesized and the structure was confirmed as described previously (9,10). VP-16, the control drug (Fig. 1B), was obtained from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). VP-16 and M3 were dissolved in dimethylsulfoxide (DMSO) and the final DMSO concentration did not exceed 0.1%. Sulforhodamine-B, colchicine and anti-α-tubulin monoclonal antibody (dilution, 1:100; cat. no. MFCD00145921) were also all purchased from Sigma-Aldrich (Merck KGaA). Alexa Fluor 555-conjugated secondary antibodies were obtained from Invitrogen; Thermo Fisher Scientific, Inc. (Waltham, MA, USA).

Cell lines and cell culture. All cell lines used in the current study (A549, HCT116, HepG2, RM, BCJ-4T, 293T and NCM460) were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The HepG2 cell line was originally considered to be derived from a hepatocellular carcinoma cell line; however, it has since been identified to originate from a hepatoblastoma (14). All cells were cultured in Dulbecco's modified Eagle’s medium (DMEM) with 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc.) and maintained at 37˚C in a humidified 5% CO₂ atmosphere. The HepG2 cell line was originally considered to be derived from a hepatocellular carcinoma cell line; however, it has since been identified to originate from a hepatoblastoma (14). All cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc.) and maintained at 37˚C in a humidified 5% CO₂ incubator. The cell lines were maintained according to the supplier's protocols. Cell culture media with 0.1% DMSO was used as a vehicle control for the in vitro experiments.

MTT assay. All cell lines were plated in 96-well plates at a density of 1x10^4 cells/well and cultured overnight at 37°C. Cells were then cultured with different concentrations (0.1, 1, 10, 100 µM) of reagents, M3 or VP16, for 72 h at 37°C with 5% CO₂. Next, 11 µl MTT (5 mg/ml; Nanjing KeyGen Biotech Co., Ltd.) was added to each well, with a final concentration of ~0.5 mg/ml, and the cells were cultured for 4 h at 37°C in a 5% CO₂ atmosphere. The purple formazan was dissolved by the addition of 10% sodium dodecyl sulfate and the absorbance was read at 570 nm using a microplate reader. The half maximal inhibitory concentration (IC₅₀) values were then calculated.

Cell morphology and apoptosis analysis. HCT116 cells were plated in 24-well plates at a density of 1x10^4 cells/well and cultured for 24 h at 37°C. Cells were then treated with different concentrations of reagents and cultured at 37°C in a humidified incubator containing 5% CO₂ for 48 h. Subsequently, 300 µl of 5 µg/ml Hoechst 33342 solution (Beijing Solarbio Science and Technology Co., Ltd., Beijing, China) was added to each well and the cells were stained in the dark for 10 min at 37°C. The morphology of the cells was observed and images were captured using a fluorescence microscope (magnification, x400).

Following treatment for 72 h with different concentrations of reagents (0.03, 0.06, 0.12, 0.25 µM M3) at 37°C, apoptosis was analyzed using the Annexin-V-FLUOS Staining kit (Roche Diagnostics, Basel, Switzerland). Briefly, the cells were harvested, washed with PBS, centrifuged with 300 x g for 5 min at 4°C and stained with 100 µl Annexin-V-FLUOS labeling solution. Cells were incubated for 10-15 min at 15-25°C and then analyzed using a flow cytometer.

Western blot analysis. HCT116 cells treated with different compounds (M3, Toxol, and Colchicine) for 72 h were lysed and cellular lysates were harvested. Lysates were centrifuged at 300 x g, at 4°C for 20 min. Protein was extracted with protein extraction buffer (cat. no. KG250; Nanjing KeyGen Biotech Co., Ltd., Protein samples were determined by bicinchoninic acid assay, and 25 µl protein were added per lane, then separated by 10% SDS-PAGE and transferred to nitrocellulose membranes. Following blocking with 5% skimmed milk for 2 h at room temperature, the membranes were washed three times with TBS buffer. The membranes were then incubated with primary antibodies at a dilution of 1:100 against β-actin, cleaved caspase-3, caspase-3 and cleaved poly(ADP-ribose) polymerase (PARP), polymerized tubulin (pellet) and soluble tubulin (supernatant) (cat. no. 4970, 9664, 9662, 9532, 2144 and 2146, respectively) Cell Signaling Technology, Inc., Danvers, MA, USA) at a dilution of 1:100 overnight at 4°C. Membranes were washed three times with a buffer containing TBS and Tween-20, and incubated with peroxidase-conjugated secondary anti-mouse or anti-rabbit antibodies (cat. no. A-11061; Thermo Fisher Scientific, Inc.) at a dilution of 1:1,000 for 2 h. Protein bands were visualized by film exposure with an enhanced chemiluminescence kit (Nanjing KeyGen Biotech Co., Ltd.) using Quantity One 4.6.6 software (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used.

Immunocytochemistry. Immunocytochemistry was performed as described previously (12,13,15). Briefly, HCT116 cells (1x10^4 cells/well) were plated in 24-well plates and grown for...
Table I. IC₅₀ values of M3 and VP-16 in various cell lines.

| Reagent | A549 IC₅₀ (µM) | HCT116 IC₅₀ (µM) | HepG2 IC₅₀ (µM) | RM IC₅₀ (µM) | 4T IC₅₀ (µM) | 293T IC₅₀ (µM) | NCM460 IC₅₀ (µM) |
|---------|----------------|-------------------|-----------------|-------------|-------------|---------------|-----------------|
| M3      | 0.87±0.14      | 0.08±0.03         | 1.12±0.14       | 0.26±0.04   | 0.52±0.05   | 28.50±3.11    | 31.80±3.13      |
| VP-16   | 21.90±2.14     | 13.80±0.15        | 7.34±0.61       | 23.80±2.14  | 14.80±1.12  | 39.50±3.98    | 40.50±5.12      |

M3, 4-O-(2',3',4'-tri-O-methyl-β-D-xylopyranosyl) diphyllin; IC₅₀, half maximal inhibitory concentration.

24 h at 37°C. Cells were treated with M3 (0.125 and 0.25 µM) at 4°C for 24 h. Cells were washed and incubated with anti-α-tubulin monoclonal antibodies (dilution, 1:100) overnight at 4°C, followed by incubation with Alexa Fluor 555-conjugated secondary antibodies (dilution, 1:100; cat. no. A-21422; Thermo Fisher Scientific, Inc.) in the dark for 2 h. Subsequently, 300 µl of 5 µg/ml Hoechst 33342 solution was added to each well and stained samples were incubated in the dark for 10 min at room temperature. Microtubules were observed and images were captured using a fluorescence microscope (magnification, x400).

**Tubulin polymerization assay.** Tubulin polymerization assays were performed as described previously (16-18). The CytoDYNAMIX Screen 03 Tubulin Polymerization assay kit was purchased from Cytoskeleton, Inc. (Denver, CO, USA). Briefly, HCT116 cells (1x10⁴ cells/ml) were seeded into a 100-mm culture dish and cultured in Dulbecco’s modified Eagle’s medium containing 0.1% dimethylsulfoxide with taxol (10 µM), colchicine (5 µM) or M3 (10, 20 or 40 µM) at 37°C for 24 h. Absorbance was measured at a wavelength of 340 nm and was recorded at 37°C every min for 60 min.

**Statistical analysis.** Data are presented as the mean ± standard error of the mean. All statistical analyses were performed using SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA). Student’s t-test was performed for paired observations and one-way analysis of variance with Fisher’s least significant difference test was performed for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**M3 inhibits proliferation of cancer cell lines.** Five cancer cell lines from various solid tumors, plus 293T cells and a normal colon epithelial cell line NCM460, were used to determine the effects of M3 (Fig. 1A) on cell proliferation using MTT assays. VP-16 (Fig. 1B) was selected as a control. The IC₅₀ values determined are presented in Table I. The mean IC₅₀ values for M3 and VP-16 in all cell lines were 0.32 µM (range, 0.08-1.12 µM) and 15.7 µM (range, 4.1-25.2 µM), respectively. This indicated that M3 exhibits a higher antiproliferative effect against tumorigenic cell lines compared with VP-16 (P<0.05; Fig. 1C). M3 inhibited proliferation of the taxol-resistant A549 cell line, with an IC₅₀ value of 0.87 µM, which was markedly lower compared with the IC₅₀ value of VP-16 (21.9 µM). The IC₅₀ value for M3 in the 293T cells was 28.5 µM, which was lower compared with the IC₅₀ value of VP-16 (39.5 µM). In addition, the IC₅₀ value of M3 in the human colon carcinoma HCT116 cell line was 0.08 µM, which was markedly lower compared with that of VP-16 (13.8 µM). Therefore, in order to further study the role of M3 in colon cancer, the current study selected HCT116 cells to investigate the initial mechanism of M3 in cancer cells, so as to further study the role of M3 in colon cancer.

**M3 induces apoptosis in HCT116 cells.** Annexin-V-FUOS staining and flow cytometry were performed to investigate the effect of M3 on the apoptosis of HCT116 cells (19-21). As demonstrated in Fig. 2A, the early and late apoptotic cell populations increased in response to M3 in a concentration-dependent manner. The proportions of the early and late apoptotic cells increased from 8.1 and 29.5%, respectively, at 0.03 µM of M3 to 11.3 and 65.1%, respectively, at 0.25 µM of M3. By contrast, the proportions of early and late apoptotic cells were 9.2 and 29.5%, respectively, when the cells were treated with 10 µM VP-16. It was then identified that the levels of cleaved caspase-3 and cleaved PARP increased upon exposure to M3 in a concentration-dependent manner, while expression level of non-cleaved caspase-3 decreased (Fig. 2B and C). This suggests that M3-induced apoptosis may be mediated by a caspase-dependent pathway. Furthermore, the proliferation rate was inhibited by M3 (Fig. 2D).

In addition, fluorescence staining was used to investigate morphological changes in HCT116 cells following treatment with different concentrations of M3 for 24 h. Cells were treated with M3, stained with Hoechst 33342 and visualized using a fluorescence microscope. Morphological changes that reflected apoptosis, including chromatin condensation and fragmentation of the nucleus, were observed in HCT116 cells treated with M3 (0.125 and 0.25 µM; Fig. 2E).

**M3 inhibits microtubule polymerization in HCT116 cells.** Immunocytochemistry, according to previously published techniques (22-24), was used to investigate the effect of M3 on microtubule networks in HCT116 cells. As demonstrated in Fig. 3, the microtubule network exhibited a normal arrangement and organization in untreated HCT116 cells. However, notable microtubule disassembly was identified in HCT116 cells treated with 0.125-0.5 µM M3 for 24 h.

Next, the effects of M3 on tubulin polymerization in vitro were compared with a tubulin depolymerizing reagent, colchicine, and a tubulin polymerizing agent, taxol. As demonstrated in Fig. 4A, following treatment with M3 for 3,000 sec, the absorbance of tubulin decreased compared with that of the control group, which was treated with DMEM and 0.1% DMSO. This
Figure 2. M3 induces apoptosis of HCT116 cells in a concentration-dependent manner. Q1 consists of dead cells, Q2 consists of late apoptotic cells, Q3 consists of early apoptotic cells, Q4 consists of non-apoptotic cells. (A) Apoptosis of HCT116 cells treated with M3 for 72 h. Annexin-V-FLUOS staining was used to detect apoptotic HCT116 cells. (B) Effect of M3 on the expression of cleaved caspase-3 and cleaved PARP in HCT116 cells. Cells were treated with various concentrations of M3 (0.03, 0.06, 0.12 and 0.25 µM) for 72 h and then examined by western blot analysis. β-actin was used for normalization. (C) Statistical analysis of densitometry. Data are presented as the mean ± standard error of the mean from three independent experiments. *P<0.05 vs. cells treated with 0 µM M3. (D) Proliferation rate of HCT166 cells treated with various concentrations of M3 and VP-16. Data are presented as the mean ± standard error of the mean from three independent experiments. *P<0.05 vs. cells treated with 0.03 µM M3. (E) Nuclear morphology of HCT116 cells following treatment with various concentrations of M3. HCT116 cells were treated with different concentrations of M3 (0, 0.125 and 0.25 µM) for 24 h. Representative images of cells stained with Hoechst 33342, observed using a fluorescence microscope, are presented. Magnification, x200. PARP, poly(ADP-ribose) polymerase; M3, 4-O-(2',3',4'-tri-O-methyl-β-D-xylopyranosyl) diphyllin; FITC, fluorescein isothiocyanate; PI, propidium iodide.

Figure 3. Effect of M3 on the organization of microtubules in HCT116 cells. HCT116 cells were treated with different concentrations of M3 (0, 0.125, 0.25 and 0.50 µM) for 24 h. Microtubules were observed by fluorescence microscopy. Magnification, x400. M3, 4-O-(2',3',4'-tri-O-methyl-β-D-xylopyranosyl) diphyllin.
indicated that treatment with M3 was associated with a decrease in the rate of microtubule assembly; however, M3 exhibited a markedly weaker effect compared with colchicine.

Additionally, the protein expression levels of polymerized tubulin (pellet) and soluble tubulin (supernatant) were observed following treatment of HCT116 cells with M3, colchicine and taxol. As demonstrated in Fig. 4B and C, the expression level of polymerized α-tubulin decreased significantly in cells treated with M3 compared with the control group. It was identified that treatment with M3 was associated with a decrease in the expression level of polymerized α-tubulin in a concentration-dependent manner. This suggests that M3 may promote microtubule depolymerization in HCT116 cells.

Discussion

The majority of cancer types are characterized by uncontrolled cell proliferation, inhibited cell differentiation and decreased contact inhibition, which provides tumor cells with the capacity to metastasize and invade local tissues (23). Several diphyllyn glycosides can inhibit cancer cell proliferation; however, to the best of our knowledge, the molecular targets of diphyllyn glycosides are unknown (4,9,10). Previous studies have identified that, at high concentrations, certain diphyllyn glycosides exhibit inhibitory effects on DNA topoisomerase II and microtubule polymerization (6,7). Therefore, the current study investigated the biological activities of M3, a diphyllyn glycoside, in cancer cells.

M3 was identified to inhibit the growth of a number of cancer cell lines in vitro, while exerting a much weaker effect in the 293T cell line and the normal colon cell line, NCM460. This suggests that M3 may potentially be used as a chemotherapeutic agent. However, further studies are required to investigate the effect of M3 on other normal colon cell lines and to clarify the mechanisms underlying the antiproliferation effect of M3 in vitro.

Microtubule-targeting agents bind to microtubules and either promote or inhibit tubulin assembly, thereby interfering with cell division and cell proliferation. These agents can exhibit marked antitumor effects and can be categorized as tubulin polymerization-promoting, tubulin polymerization-inhibiting or tubulin-depolymerizing agents (11,15,20,23). Taxol, serve an important role in cancer therapy; however, its side effects include bone marrow suppression, neurotoxicity and multidrug resistance, which limits their clinical applications (20-22). The current study identified that M3 exhibits similar effects on cellular microtubule assembly in HCT116 cells compared with the tubulin-depolymerizing reagent colchicine. This suggests that M3 may be used as a microtubule inhibitor in cancer treatment.

Microtubule inhibitors can also induce apoptosis via a number of different mechanisms. Paclitaxel can activate and regulate numerous genes associated with apoptosis, including Fas, Fas ligand, p53, p21, the Bcl family and the caspase family (23,24). Apoptosis is characterized by morphological changes, including cell shrinkage, cytoplasmic blebbing, chromatin condensation, DNA fragmentation and caspase

Figure 4. Effect of M3 on microtubule assembly in HCT116 cells. (A) M3 inhibits microtubule assembly in vitro. Microtubule assembly assays were performed using a Tubulin Polymerization assay kit. Cells (1 x 10^6 cells/ml) were incubated with taxol (10 µM), colchicine (5 µM) or M3 (10, 20 or 40 µM). Cells in the control group were incubated in Dulbecco’s modified Eagle’s medium containing 0.1% dimethylsulfoxide. Absorbance at 340 nm was recorded at 37˚C every min for 60 min. (B) M3 inhibits microtubule assembly in HCT116 cells. HCT116 cells were treated with taxol (0.5 µM), colchicine (0.5 µM) or M3 (0.125, 0.25 or 0.5 µM) for 24 h. The expression of α-tubulin was detected by western blot analysis. (C) The relative protein expression level of polymerized α-tubulin. *P<0.05 vs. con. M3, 4-O-(2',3',4'-tri-O-methyl-β-D-xylopyranosyl) diphyllyn; con, control.
activation (11,24). The current study revealed that M3 induces apoptosis of HCT116 cells at a lower concentration compared with VP-16. In addition, an increased level of caspase-3 was detected in M3-treated HCT116 cells compared with control cells, which indicates that M3 may induce apoptosis in a caspase-3-dependent manner.

In conclusion, the current study demonstrated that M3 inhibits the proliferation of HCT116 cells and induces apoptosis in a caspase-3-dependent manner. This provides a basic understanding of the anticancer effect of M3 in HCT116 cells. However, to further investigate its potential use as an anticancer agent, the precise underlying mechanism of M3 should be investigated in future in vitro and in vivo studies.

Acknowledgements

Not applicable.

Funding

The current study was supported by the Natural Science Foundation of Jiangsu Province (grant no. BK20171157).

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

HC, TZ conducted the study. WS collected all the data and analyzed. YZ provided the M3 and designed the study. SW and PL were responsible for the design and conduction of the study. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Weymouth-Wilson AC: The role of carbohydrates in biologically active natural products. Nat Prod Rep 14: 99-110, 1997.
2. Seeberger PH and Wel DB: Automated synthesis of oligosaccharides as a basis for drug discovery. Nat Rev Drug Discov 4: 751-763, 2005.
3. Gui M, Shi DK, Huang M, Zhao Y, Sun QM, Zhang J, Chen Q, Feng JM, Liu CH, Li M, et al: D11, a novel glycosylated diphyllin derivative, exhibits potent anticancer activity by targeting topoisomerase II. Invest New Drugs 29: 800-810, 2011.
4. Shi DK, Zhang W, Ding N, Li M and Li YX: Design, synthesis and biological evaluation of novel glycosylated diphyllin derivatives as topoisomerase II inhibitors. Eur J Med Chem 47: 424-431, 2012.
5. Pradheepkumar CP, Panneeselvam N and Shanmugam G: Cleistanthin A causes DNA strand breaks and induces apoptosis in cultured cells. Mutat Res 464: 185-193, 2000.
6. You Y: Podophyllotoxin derivatives: Current synthetic approaches for new anticancer agents. Curr Pharm Des 11: 1695-1717, 2005.
7. Meenakshi J and Shanmugam G: Cleistanthin A, a diphyllin glycoside from Cleistanthus collinus, is cytotoxic to PHA-stimulated (proliferating) human lymphocytes. Drug Dev Res 51: 187-190, 2000.
8. Hemmati S, Schneider B, Schmidt T, Fedderk H, Allermann AW and Fuss E: Justicidin B 7-hydroxylase, a cytochrome P450/